CVS Health Co. (NYSE:CVS) Stock Holdings Lowered by Greatmark Investment Partners Inc.

Greatmark Investment Partners Inc. lowered its position in shares of CVS Health Co. (NYSE:CVS) by 58.2% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 128,263 shares of the pharmacy operator’s stock after selling 178,639 shares during the period. Greatmark Investment Partners Inc.’s holdings in CVS Health were worth $5,758,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Versor Investments LP bought a new position in CVS Health in the 3rd quarter valued at about $371,000. GSA Capital Partners LLP bought a new position in CVS Health in the 3rd quarter valued at about $816,000. Aptus Capital Advisors LLC grew its position in CVS Health by 7.7% in the 3rd quarter. Aptus Capital Advisors LLC now owns 12,078 shares of the pharmacy operator’s stock valued at $759,000 after buying an additional 865 shares in the last quarter. MQS Management LLC bought a new position in CVS Health in the 3rd quarter valued at about $237,000. Finally, Oppenheimer & Co. Inc. grew its position in CVS Health by 5.6% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 99,848 shares of the pharmacy operator’s stock valued at $6,278,000 after buying an additional 5,325 shares in the last quarter. Institutional investors own 80.66% of the company’s stock.

Insider Buying and Selling

In related news, SVP James David Clark sold 7,513 shares of the stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total transaction of $498,487.55. Following the completion of the sale, the senior vice president now directly owns 8,394 shares in the company, valued at approximately $556,941.90. This trade represents a 47.23 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Michael F. Mahoney acquired 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The shares were purchased at an average price of $66.70 per share, with a total value of $2,001,000.00. Following the completion of the acquisition, the director now owns 39,356 shares of the company’s stock, valued at $2,625,045.20. This represents a 320.65 % increase in their position. The disclosure for this purchase can be found here. 0.24% of the stock is owned by corporate insiders.

CVS Health Price Performance

CVS opened at $65.63 on Friday. The stock has a fifty day moving average of $58.47 and a 200-day moving average of $57.00. The firm has a market capitalization of $82.75 billion, a P/E ratio of 17.93, a PEG ratio of 0.98 and a beta of 0.53. CVS Health Co. has a 12-month low of $43.56 and a 12-month high of $80.75. The company has a quick ratio of 0.60, a current ratio of 0.81 and a debt-to-equity ratio of 0.80.

CVS Health (NYSE:CVS) last released its earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. Equities analysts forecast that CVS Health Co. will post 5.89 EPS for the current fiscal year.

CVS Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, February 3rd. Investors of record on Thursday, January 23rd were issued a dividend of $0.665 per share. The ex-dividend date was Thursday, January 23rd. This represents a $2.66 annualized dividend and a dividend yield of 4.05%. CVS Health’s dividend payout ratio is 72.68%.

Wall Street Analyst Weigh In

CVS has been the subject of a number of recent analyst reports. Piper Sandler decreased their target price on shares of CVS Health from $72.00 to $64.00 and set an “overweight” rating for the company in a research report on Monday, November 25th. Argus set a $77.00 price target on shares of CVS Health in a report on Tuesday, February 18th. Leerink Partners raised shares of CVS Health from a “market perform” rating to an “outperform” rating and upped their price target for the company from $55.00 to $75.00 in a report on Thursday, February 13th. Cantor Fitzgerald raised shares of CVS Health from a “neutral” rating to an “overweight” rating in a report on Wednesday, February 12th. Finally, Wells Fargo & Company upped their price target on shares of CVS Health from $68.00 to $73.00 and gave the company an “overweight” rating in a report on Thursday, February 13th. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $69.83.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.